Risk factors for cryptococcal meningitis in HIV-infected patients

AIDS Research and Human Retroviruses

Volumn 15, Issue 7, 1999, Pages 625-631

  Oursler, Kris Ann K ^a   Moore, Richard D ^a   Chaisson, Richard E ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; STEROID;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FUNGAL MENINGITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE STATUS; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; PRIORITY JOURNAL; RISK ASSESSMENT;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIFUNGAL AGENTS; CASE-CONTROL STUDIES; CEREBROSPINAL FLUID; COHORT STUDIES; FEMALE; FLUCONAZOLE; GLUCOCORTICOIDS; HUMANS; MALE; MENINGITIS, CRYPTOCOCCAL; PREDNISONE; RISK FACTORS; SURVIVAL ANALYSIS; URBAN POPULATION;

EID: 0033136065     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922299310926     Document Type: Article

References (30)

1. Levy RM, Bredesen DE, and Rosenblum ML: Neurological manifestations of the acquired immunodeficiency syndrome (AIDS): Experience at UCSF and review of the literature. J Neurosurg 1985;62:475-495.
2. Curie BP and Casadevall A: Estimation of the prevalence of cryptococcal infection among patients infected with the human immunodeficiency virus in New York City. Clin Infect Dis 1994;19: 1029-1033.
3. Kovacs JA, Kovacs AA, Polis M, et al.: Cryptococcosis in the acquired immunodeficiency syndrome. Ann Intern Med 1985;103: 533-538.
4. Zuger A, Louie E, Holzman RS, Simberkoff MS, and Rahal JJ: Cryptococcal disease in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1986;104:234-240.
5. Levitz SM: The ecology of Cryptococcus neoformans and the epidemiology of cryptococcosis. Rev Infect Dis 1991;13:1163-1169.
6. Saag MS, Powderly WG, Cloud GA, et al.: Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. N Engl J Med 1992;326:83-89.
7. White M, Cirrincione C, Blevins A, and Armstrong D: Cryptococcal meningitis: Outcome in patients with AIDS and patients with neoplastic disease. J Infect Dis 1992;165:960-963.
8. Chuck SL and Sande MA: Infections with Cryptococcus neoformans in the acquired immunodeficiency syndrome. N Engl J Med 1989;321:794-799.
9. Diamond RD and Bennett JE: Prognostic factors in cryptococcal meningitis: A study in 111 cases. Ann Intern Med 1974;80: 176-181.
10. Dismukes WE, Cloud G, Gallis HA, et al.: Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. N Engl J Med 1987;317: 334-341.
11. Butler WT, Alling DW, Spickard A, and Utz JP: Diagnostic and prognostic value of clinical and laboratory findings in cryptococcal meningitis. N Engl J Med 1964;270:59-66.
12. Dromer F, Mathoulin S, Dupont B, Laporte A, and the French Cryptococcosis Study Group: Epidemiology of cryptococcosis in France: A 9-year survey (1985-1993). Clin Infect Dis 1996;23:82-90.
13. Darras-Joly C, Chevret S, Wolff M, et al.: Cryptococcus neoformans infection in France: Epidemiologic features of and early prognostic parameters for 76 patients who were infected with human immunodeficiency virus. Clin Infect Dis 1996;23:369-376.
14. Rozenbaum R and Gonçalves AJR: Clinical epidemiological study of 171 cases of cryptococcosis. Clin Infect Dis 1994;18:369-380.
15. Lewis JL and Rabinovich S: The wide spectrum of cryptococcal infections. Am J Med 1972;53:315-322.
16. Pradier C, Bernard E, Lubick L, et al.: Does fluconazole prevent cryptococcal meningitis in human immunodeficiency virus-infected patients? J Infect Dis 1992;165:787. [Letter]
17. Pinner RW, Hajjeh RA, and Powderly WG: Prospects for preventing cryptococcosis in persons infected with human immunodeficiency virus. Clin Infect Dis 1995;21:S103-S107.
18. Moosa MYS and Coovadia YM: Cryptococcal meningitis in Durban, South Africa: A comparison of clinical features, laboratory findings, and outcome for human immunodeficiency virus (HIV)-positive and HIV-negative patients. Clin Infect Dis 1997;24:131-134.
19. Clark RA, Greer D, Atkinson W, Valainis GT, and Hyslop NE: Spectrum of Cryptococcus neoformans infection in 68 patients infected with human immunodeficiency virus. Rev Infect Dis 1990;12(5):768-777.
20. Powderly WG, Finkelstein DM, Feinberg J, et al.: A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. N Engl J Med 1995;332:700-705.
21. 3: Demonstration of efficacy in a prospective, multicenter trial. Clin Infect Dis 1996;23:1282-1286.
22. Quagliarello VJ, Viscoli C, and Horwitz RI: Primary prevention of cryptococcal meningitis by fluconazole in HIV-infected patients. Lancet 1992;345:548-552.
23. Ammassari A, Linzalone A, Murri R, Marasca G, Morace G, and Antinori A: Fluconazole for primary prophylaxis of AIDS-associated cryptococcosis: A case-control study. Scan J Infect Dis 1995;27:235-237.
24. Nightingale SD, Cal SX, Peterson DM, et al.: Primary prophylaxis with fluconazole against systemic fungal infections in HIV-positive patients. AIDS 1992;6:191-194.
25. Chaisson RE, Keruly JC, and Moore RD: Race, sex, drug use and the progression of HIV disease. N Engl J Med 1995;333:751-756.
26. Moore RD and Chaisson RE: Natural history of opportunistic disease in an HIV-infected urban clinical cohort. Ann Intern Med 1996;124:633-642.
27. Fleiss JL: Statistical Methods for Rates and Proportions. John Wiley & Sons, New York, 1981.
28. Chaisson RE, Gallant JE, Keruly JC, and Moore RD: Impact of opportunistic disease on survival in patients with HIV infection. AIDS 1998;12:29-33.
29. Sorvillo F, Beall G, Turner PA, Beer VL, Kovacs AA, and Kerndt PR: Incidence and factors associated with extrapulmonary cryptococcosis among persons with HIV infection in Los Angeles County. AIDS 1997;11:673-679.
30. Gallant JE, Chaisson RE, and Moore RD: The effect of adjunctive corticosteroids for the treatment of Pneumocystis carinii pneumonia on mortality and subsequent complications. Chest 1998;114(5): 1258-1263.